Financial Daily from THE HINDU group of publications
Sunday, Jan 29, 2006
Financial Daily from THE HINDU group of publications Sunday, Jan 29, 2006 |
|
|
|
|
|
|
|
Corporate
-
Regulatory Bodies & Rulings Orchid gets USFDA nod for Cefoxitin Our Bureau
Chennai , Jan. 28 ORCHID Chemicals & Pharmaceuticals Ltd said it has received the formal approval from the USFDA for its ANDA (Abbreviated New Drug Application) for Cefoxitin for injection, 1 gm/vial and 2gm/vial. Cefoxitin is the generic version of Merck's Mefoxin. Orchid is launching this product in the US exclusively through Apotex. A company spokesman told Business Line that the size of the "genericised" market is $38 million. The other player in the business is American Pharmaceutical Partners, Inc. In a press release, Orchid's Managing Director, Mr K. Raghavendra Rao, has observed that Orchid was the second generic company to enter the market and "hence we expect a good market share and revenues."
More Stories on : Regulatory Bodies & Rulings
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2006, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|